Impact of fingolimod on CD4+T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients

Kurtuncu, Murat; Yilmaz, Vuslat; Akcay, Halil; Turkoglu, Recai; Altunrende, Burcu; Cinar, Suzan; Ulusoy, Canan; Gunduz, Tuncay; Icoz, Sema; Kasap, Mithat; Caliskan, Zeynep; Otunc, Gokturk; Eraksoy, Mefküre; Tuzun, Erdem

doi:10.1016/j.jneuroim.2019.577065

Impact of fingolimod on CD4+T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients

Copy For Citation

Kurtuncu M., Yilmaz V., Akcay H. I., Turkoglu R., Altunrende B., Cinar S., ...More

JOURNAL OF NEUROIMMUNOLOGY, vol.337, 2019 (SCI-Expanded)

Publication Type: Article / Article
Volume: 337
Publication Date: 2019
Doi Number: 10.1016/j.jneuroim.2019.577065
Journal Name: JOURNAL OF NEUROIMMUNOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Keywords: Fingolimod, Sphingosine-1-phosphate receptor, Cytokine, Chemokine, T cell, REGULATORY T-CELLS, ORAL FINGOLIMOD, INTERFERON, EXPRESSION, TH17
Istanbul University Affiliated: Yes

Abstract

Fingolimod inhibits the egress of lymphocytes from lymphatic tissues and also directly affects their functions by modulation of the sphingosine-1 -phosphate receptor 1 (S1P1). Our aim was to evaluate the impact of fingolimod on diverse CD4+ T cell subsets, and cytokines.